Jordan E. Lake
Houston AIDS Research Team CRS · The University of Texas Health Science Center, Houston · University of California, Los Angeles
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
6
all conditions, ClinicalTrials.gov
NIH grants tied to them
9
1 more share only the name and are not shown
Trial papers
26
PubMed author-name match
Trials
Studies that name Jordan E. Lake as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07871552 · Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIVThe University of Texas Health Science Center, Houston · not yet recruiting · Epigenetic Aging
- Ph2NCT06005610 · Estradiol Therapy In Transgender Women to Research Interactions With HIV TherapyNational Institute of Allergy and Infectious Diseases (NIAID) · terminated · HIV I Infection · study chair
- Ph2NCT04216589 · Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)National Institute of Allergy and Infectious Diseases (NIAID) · completed · HIV Infections, Non-Alcoholic Fatty Liver Disease · study chair
- Ph4NCT03348163 · (mo)BETTA Trial in Transwomen for Optimization of ARTThe University of Texas Health Science Center, Houston · terminated · HIV Infections
- Ph2NCT01928927 · Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · completed · HIV-1 Infection · study chair
- Ph2NCT01578772 · A Clinical Trial for People HIV+ Age > 50 at Risk for Heart DiseaseUniversity of California, Los Angeles · completed · Endothelial Dysfunction · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Evaluation of Glucagon-Like Peptide-1 Receptor Agonist on Pathophysiology of Inflammation and Atherosclerosis in Persons Living With HIV: A Multicenter Randomized Placebo-Controlled TriR01HL184987 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2026 · $1,282,827 awarded in 2026Same name and institution; not confirmed by an ID
- Preparing for Semaglutide Microdosing to Maintain Cardiovascular Health in People with HIV: The (pre-)SMASH CVD TrialR34HL182386 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · fiscal years 2026 · $255,458 awarded in 2026Same name and institution; not confirmed by an ID
- Estrogen's Impact on IgG Glycomic Modulation of Immunity and Inflammation During HIVR01AI189353 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · fiscal years 2025 · $2,461,651 awarded in 2025Same name and institution; not confirmed by an ID
- Incretin Microdosing for Cardiometabolic Health in People With HIV: The REINFORCE TrialR01DK142171 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · fiscal years 2025 · $966,521 awarded in 2025Same name and institution; not confirmed by an ID
- Metabolic impact of FGF-21 in adipose tissue and liver of PLWHR01DK126042 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · fiscal years 2020 to 2024 · $640,903 awarded in 2024Same name and institution; not confirmed by an ID
- Comprehensive HIV+/- Analysis of iNflammation in transGender women on Estrogen Supplementation: The CHANGES StudyR21AI143452 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · fiscal years 2019 to 2020 · $178,526 awarded in 2020Same name and institution; not confirmed by an ID
- Understanding Contributions of HIV Infection and Feminizing Hormone Use to Cardiometabolic Risk Among Transgender WomenR03AI141014 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · fiscal years 2018 to 2019 · $77,000 awarded in 2019Same name and institution; not confirmed by an ID
- Inflammation, Fibrosis and End-Organ Disease in HIV-Infected AdultsK23AI110532 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · fiscal years 2014 to 2018 · $185,760 awarded in 2018Same name and institution; not confirmed by an ID
- CBT and Exercise to Reduce Pain and Substance Use in Older Adults with HIVR21DA038163 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2014 to 2015 · $167,816 awarded in 2015Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership and Operations Center (LOC), AIDS Clinical Trials GroupUM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · fiscal years 2011 to 2026Named on NCT01928927
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:51 UTC. The ranking covers the 200 most relevant of 26 PubMed records, and a shared surname and initials can bring in a namesake. All 26 on PubMed
- Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.Antivir Ther · 201792 citationsRCR 4.0
- Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.Clin Infect Dis · 202539 citationsRCR 11.2
- Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy.Nutr J · 201538 citationsRCR 1.6
- 35 citationsRCR 1.3
- 32 citationsRCR 1.3
- Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.Lancet Infect Dis · 202229 citationsRCR 1.9
- Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone.J Infect Dis · 201826 citationsRCR 1.0
- A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.Clin Infect Dis · 201926 citationsRCR 1.2
- A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.AIDS Patient Care STDS · 201224 citationsRCR 0.8
- Antiretroviral initiation is associated with increased skeletal muscle area and fat content.AIDS · 201724 citationsRCR 1.1